Application No.: 10/084,621

Response to Final Office Action dated August 13, 2003

Response filed November 13, 2003

REMARKS

Claims 1-2, 5-9, 11-26, 40-49 and 60-63 are pending in the application. Claims 1, 40, 41 and 49 have been amended and claims 8-9, 11-26 and 60-63 are canceled without prejudice to future presentation. It is believed that the amendments do not constitute new matter and their entry is requested.

Objections to the Specification

The Examiner has objected to the specification for improperly including a hyperlink. The hyperlink has been deleted and replaced with the name of the company represented by the hyperlink. It is believed that the amendment has overcome this objection and its withdrawal is requested.

35 U.S.C. 112, 1st paragraph rejections

Claims 1-2, 5-9, 11-25, 40-49 and 60-63 were rejected for lack of enablement. At page 3 of the latest Action, the Examiner states that the specification is enabling for a transgenic mouse whose genome comprises a homozygous disruption of the endogenous Gpx1 and Gpx2 genes, wherein the mouse exhibits one of the disclosed phenotypes. The Examiner goes on to assert, however, that the claims are overly broad since they encompass a model for cancer and "the evidence of record may be suggestive of a phenotype of cancer of the small intestine at best."

The claims have been canceled or amended where appropriate to encompass a transgenic mouse whose genome comprises a homozygous disruption of the endogenous Gpx1 and Gpx2 genes or a transgenic mouse with said disruptions wherein the mouse exhibits one of the disclosed phenotypes.

Based on the amendments to the claims, it is believed that this rejection has been overcome and that the claims as amended are enabled by the disclosure provided. Withdrawal of this rejection is requested.

Application No.: 10/084,621

Response to Final Office Action dated August 13, 2003

Response filed November 13, 2003

CONCLUSION

In view of the above amendments and remarks, it is believed that the claims satisfy the requirements of the patent statutes and reconsideration of the instant application and early notice of allowance are requested. The Examiner is invited to telephone the undersigned if it is deemed to expedite allowance of the application.

RESPECTFULLY SUBMITTED,							
	Michael J. Moran, Ph.D., Registration No. 42,013						
SIGNATURE	mulae	mulad Inwan			November	November 13, 2003	
Address	Rothwell, Figg, Ernst & Manbeck Suite 800, 1425 K Street, N.W.						
City	Washington	State	D.C.		Zip Code	20005	
Country	U.S.A.	Telephone	202-783-6040		Fax	202-783-6031	

1954-397.am2.wpd